Aula sobre Trasplantes de Órganos Sólidos - Roche Trasplantes

43. Gaston RS, Hudson SL, Julian BA, et al. Impact of donor/recipientsize matching on outcomes in renal transplantation.Transplantation 1996; 61: 383.44. Raine AEG. Does antihypertensive therapy modify chronic allograftfailure?. Kidney Int 1995; 48 Suppl 52: 2.45. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graftfailure with recipient blood pressure. Kidney Int 1998; 53 :217.46. Mourad G, Ribstein J, and Mimram A. Converting-enzme inhibitorversus calcium antagonist in cyclosporine treated renaltransplants. Kidney Int 1993; 43: 419.47. Benediktsson H, Chea R, Davidoff A, Paul LC. Antihypertensivedrug treatmentin chronic renal allograft rejection in therat: Effect on structure and function. Transplantation 1996; 62:1634.48. Amuchastegui SC, Azzollini N, Mister M, Pezzotta A, PericoN, Remuzz G. Chronic allograft nephropathy in the rat is improvedby angiotensin II receptor blockade but not by calciumchannel antagonism. J Am Soc Nephrol 1998; 9: 1948.49. Bochicchio T, Sandoval G, Ron O, Perez-Grovas H, Bordes J,Herrera-Acosta J. Fosinopril prevents hyperfiltration and decreasesproteinuria in post-transplant hypertensives. KidneyInt 1990; 38: 873.50. Kagami S, Border W, Miller D, Nobel N. Angiotensin II stimulatesextracellular matrix synthesis through induction oftransforming growth factor-beta expression in rat glomerularmesangial cells. J Clin Invest 1994; 93: 2421.51. D. del Castillo, JM Campistol, L. Guirado, L. Capdevila, JGMartínez, P. Pereira, J. Bravo, R. Pérez. Efficacy and safety oflosartan in the treatment of hypertension in renal transplant recipients.Kidney International 1998, 54, Suppl. 68: s-135-s139.52. JM Campistol, PJ Iñigo, N Esforzado, D. Del Castillo. Renoprotectiveeffect (antihypertensive and antiproteinuric) of Losartanin renal transplant recipients. J Am Soc Nephrol 1999;10: 754A.53. AST54. Noris M, Azzolini N, Pezzota A, Mister M, Benigni A, MarchettiG, Gagliardini E, Perico N, Remuzzi G. Combined tratmentwuith Micophenolate Mofetil and an Angiotensin II receptorantagonist fuly protects from chronic rejection in a rat modelof renal allograft. J Am Soc Nephrol 2001; 12:1937-1946.55. Guijarro C, Massy ZA, Kasiske BL. Clinical correlation betweenrenal allograft failure and hiperlipidemia. Kidney Int1995; 52 Suppl 48: 56.56. MR Weir, JC Fink, DS Hanes, J Gardner, DK Klassen, C Cangro,E Schweitzer, ST Barlett. Chronic allograft nephropathy;Effect of Cyclosporine reduction and addition of Mycophenolatemofetil on progression of renal disease. Transplantationproceedings 1999; 31: 1286.144